Martin Shkreli : Wealth Report Net Worth 2026: Career Earnings & Assets

As of April 2026, Martin Shkreli is a hot topic. Official data on Martin Shkreli's Wealth. The rise of Martin Shkreli is a testament to hard work. Let's dive into the full report for Martin Shkreli.

Martin Shkreli, born on March 17, 1983, in Brooklyn, New York, is an American investor and businessman. He co-founded hedge funds Elea Capital, MSMB Capital Management, and MSMB Healthcare, and served as CEO for pharmaceutical firms Retrophin and Turing Pharmaceuticals. Shkreli gained notoriety in 2015 for significantly increasing the price of the antiparasitic drug Daraprim. In 2017, he was convicted of securities fraud and sentenced to seven years in prison, from which he was released in May 2022.

Net Worth and Lifestyle

At his peak, Shkreli’s net worth was estimated at $70 million. However, following legal issues and financial penalties, his net worth significantly decreased. In May 2023, he was reported to be earning $2,500 per month as a consultant for a small law firm.

Education

Shkreli attended Hunter College High School but sources differ on whether he graduated or was expelled before his senior year. He later earned a bachelor’s degree in business administration from Baruch College in 2004.

Charitable Work and Legacy

Shkreli’s legacy is marred by controversy, particularly his role in the Daraprim price hike and subsequent legal troubles. In 2022, he was fined $64.6 million in a civil antitrust case and banned for life from the pharmaceutical industry.

In 2011, Shkreli co-founded Retrophin, a biotechnology firm focused on rare diseases. He served as CEO until 2014, when he was ousted by the company’s board. The following year, he founded Turing Pharmaceuticals, where he gained infamy for acquiring the antiparasitic drug Daraprim and raising its price from $13.50 to $750 per pill.

Early Life and Family Background

Martin Shkreli was born to Albanian immigrant parents who worked as janitors, raising him and his three siblings in a working-class community in Sheepshead Bay, Brooklyn. Raised Roman Catholic, Shkreli attended Sunday school during his childhood. He developed an early interest in chemistry, influenced by a family member’s struggle with treatment-resistant depression.

Notable Works and Achievements

Shkreli’s tenure at Turing Pharmaceuticals brought him significant attention, particularly for the Daraprim price hike, which sparked widespread criticism and debates about pharmaceutical ethics. In 2015, he purchased the sole copy of Wu-Tang Clan’s album “Once Upon a Time in Shaolin” for $2 million, adding to his controversial public image.

Personal Life and Relationships

In December 2020, Shkreli was reported to be in a relationship with Christie Smythe, a former Bloomberg News reporter who had covered his arrest. By October 2021, Smythe stated they had broken up but remained friends. In October 2023, it was revealed that Shkreli had a romantic relationship with Madison Campbell, CEO of Leda Health, between February and August 2023.

Future Plans and Impact on Culture

Since his release from prison, Shkreli has ventured into software development and maintains a presence on YouTube, where he discusses finance and investing. His actions have sparked discussions about pharmaceutical ethics and corporate responsibility, leaving a lasting impact on public discourse.

Career Beginnings and Key Milestones

At 17, Shkreli interned at Cramer, Berkowitz & Company, marking his entry into the financial sector. He later worked as an analyst at Intrepid Capital Management and UBS Wealth Management. In 2006, he founded his first hedge fund, Elea Capital Management.

Recent News

In October 2024, the U.S. Supreme Court declined to hear Shkreli’s appeal against a $64.6 million penalty related to the Daraprim price hike, effectively upholding the financial judgment and his lifetime ban from the pharmaceutical industry.

Disclaimer: Martin Shkreli wealth data updated April 2026.